Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AN INTERVENTIONAL PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED STUDY TO INVESTIGATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE ASCENDING DOSES OF PF-08656795 IN ADULTS WITH OVERWEIGHT OR OBESITY

NCT07876518 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT07876518
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07876518 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AN INTERVENTIONAL PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED STUDY TO INVESTIGATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE ASCENDING DOSES OF PF-08656795 IN ADULTS WITH OVERWEIGHT OR OBESITY
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 30, 2026
Completion date
November 16, 2028
Enrollment
150 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

overweight and/or obesity